Role of TWEAK and Fn14 in tumor biology

Frontiers in Bioscience

Volumn 12, Issue 7, 2007, Pages 2761-2771

  Winkles, Jeffrey A ^a   Tran, Nhan L ^b   Brown, Sharron A N ^a   Stains, Nichole ^a   Cunliffe, Heather E ^b   Berens, Michael E ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Fn14; Inflammation; Neoplasia; TNF; Tumor; Tumor necrosis factor; TWEAK

Indexed keywords

TNFSF12 PROTEIN, HUMAN; TNFSF12 PROTEIN, MOUSE; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANIMAL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; HUMANS; INFLAMMATION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTORS;

EID: 34648869728     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2270     Document Type: Review

References (87)

1. Chicheportiche, Y., P. R. Bourdon, H. Xu, Y. Hsu, H. Scott, C. Hession, I. Garci and J. L. Browning: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272, 32401-32410 (1997) (Pubitemid 28011923)
2. Wiley, S. R. and J. A. Winkles: TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14, 241-249 (2003) (Pubitemid 36693144)
3. Campbell, S., J. Michaelson, L. Burkly and C. Putterman: The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 9, 2273-2284 (2004)
4. Baxter, F. O., P. J. Came, K. Abell, B. Kedjouar, M. Huth, K. Rajewsky, M. Pasparakis and C. J. Watson: IKKβ/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 133, 3385-3394 (2006)
5. Meighan-Mantha, R. L., D. K. W. Hsu, Y. Guo, S. A. N. Brown, S. Y. Feng, K. A. Peifley, G. F. Alberts, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, C. M. Richards and J. A. Winkles: The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274, 33166-33176 (1999) (Pubitemid 129535361)
6. Feng, S. Y., Y. Guo, V. M. Factor, S. S. Thorgeirsson, D. W. Bell, J. R. Testa, K. A. Peifley and J. A. Winkles: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156, 1253-1261 (2000) (Pubitemid 30660004)
7. Wiley, S. R., L. Cassiano, T. Lofton, T. Davis-Smith, J. A. Winkles, V. Lindner, H. Liu, T. O. Daniel, C. A. Smith and W. C. Fanslow: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837-846 (2001) (Pubitemid 34008510)
8. Brown, S. A. N., H. N. Hanscom, H. Vu, S. A. Brew and J. A. Winkles: TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 397, 297-304 (2006) (Pubitemid 44076899)
9. Brown, S. A. N., C. M. Richards, H. N. Hanscom, S. L. Feng and J. A. Winkles: The Fn14 cytoplasmic tail binds tumour necrosis factor receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem J 371, 395-403 (2003) (Pubitemid 36547622)
10. Tran, N. L., W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles and M. E. Berens: The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF-κB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280, 3483-3492 (2005) (Pubitemid 40223813)
11. Winkles, J. A., N. L. Tran and M. E. Berens: TWEAK and Fn14: New molecular targets for cancer therapy? Cancer Lett 235, 11-17 (2005)
12. Saitoh, T., M. Nakayama, H. Nakano, H. Yagita, N. Yamamoto and S. Yamaoka: TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J Biol Chem 278, 36005-36012 (2003) (Pubitemid 37139919)
13. Bossen, C., K. Ingold, A. Tardivel, J. L. Bodmer, O. Gaide, S. Hertig, C. Ambrose, J. Tschopp and P. Schneider: Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281, 13964-13971 (2006) (Pubitemid 43848322)
14. Dempsey, P. W., S. E. Doyle, J. Q. He and G. Cheng: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 14, 193-209 (2003) (Pubitemid 36693141)
15. Han, S., K. Yoon, K. Lee, K. Kim, H. Jang, N. K. Lee, K. Hwang and L. S. Young: TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-κB through TNF receptor-associated factors. Biochem Biophys Res Commun 305, 789-796 (2003) (Pubitemid 36597832)
16. Donohue, P. J., C. M. Richards, S. A. N. Brown, H. N. Hanscom, J. Buschman, S. Thangada, T. Hla, M. S. Williams and J. A. Winkles: TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 23, 594-600 (2003) (Pubitemid 36438071)
17. Xu, H., A. Okamoto, J. Ichikawa, T. Ando, K. Tasaka, K. Masuyama, H. Ogawa, H. Yagita, K. Okumura and A. Nakao: TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 318, 422-427 (2004) (Pubitemid 38553796)
18. Jin, L., A. Nakao, M. Nakayama, N. Yamaguchi, Y. Kojima, N. Nakano, R. Tsuboi, K. Okumura, H. Yagita and H. Ogawa: Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 122, 1175-1179 (2004) (Pubitemid 38651092)
19. Kim, S. H., Y. J. Kang, W. J. Kim, D. K. Woo, Y. Lee, D. I. Kim, Y. B. Park, B. S. Kwon, J. E. Park and W. H. Lee: TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68, 396-399 (2004) (Pubitemid 38470720)
20. Campbell, S., L. C. Burkly, H. X. Gao, J. W. Berman, L. Su, B. Browning, T. Zheng, L. Schiffer, J. S. Michaelson and C. Putterman: Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 176, 1889-1898 (2006) (Pubitemid 43134334)
21. Dogra, C., H. Changotra, S. Mohan and A. Kumar. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-κB and degradation of myoD protein. J Biol Chem 281, 10327-10336 (2006) (Pubitemid 43864571)
22. Potrovita, I., W. Zhang, L. Burkly, K. Hahm, J. Lincecum, M. Z. Wang, M. H. Maurer, M. Rossner, A. Schneider and M. Schwaninger: Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 24, 8237-8244 (2004) (Pubitemid 39280803)
23. Lynch, C. N., Y. C. Wang, J. K. Lund, Y. Chen, J. A. Leal and S. R. Wiley: TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274, 8455-8459 (1999) (Pubitemid 29164634)
24. Harada, N., M. Nakayama, H. Nakano, Y. Fukuchi, H. Yagita and K. Okumura: Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 299, 488-493 (2002) (Pubitemid 35365656)
25. Desplat-Jego, S., S. Varriale, R. Creidy, R. Terra, D. Bernard, M. Khrestchatisky, S. Izui, Y. Chicheportiche and J. Boucraut: TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133, 116-123 (2002) (Pubitemid 35346733)
26. Michaelson, J. S., S. Cho, B. Browning, T. S. Zheng, J. M. Lincecum, M. Z. Wang, Y. M. Hsu and L. C. Burkly: Tweak induces mammary epithelial branching morphogenesis. Oncogene 24, 2613-2624 (2005) (Pubitemid 40593089)
27. Jakubowski, A., C. Ambrose, M. Parr, J. M. Lincecum, M. Z. Wang, T. S. Zheng, B. Browning, J. S. Michaelson, M. Baetscher, B. Wang, D. M. Bissell and L. C. Burkly: TWEAK induces liver progenitor cell proliferation. J Clin Invest 115, 2330-2340 (2005) (Pubitemid 41266195)
28. Jakubowski, A., B. Browning, M. Lukashev, I. Sizing, J. S. Thompson, C. D. Benjamin, Y. Hsu, C. Ambrose, T. S. Zheng and L. C. Burkly: Dual role for TWEAK in angiogenic regulation. J Cell Sci 115, 267-274 (2002) (Pubitemid 34145176)
29. Tran, N. L., W. S. McDonough, P. J. Donohue, J. A. Winkles, T. J. Berens, K. R. Ross, D. B. Hoelzinger, C. Beaudry, S. W. Coons and M. E. Berens: The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162, 1313-1321 (2003) (Pubitemid 36350675)
30. Schneider, P., R. Schwenzer, E. Haas, F. Muhlenbeck, G. Schubert, P. Scheurich, J. Tschopp and H. Wajant: TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 29, 1785-1792 (1999) (Pubitemid 29265533)
31. Wilson, C. A. and J. L. Browning: Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 9, 1321-1333 (2002) (Pubitemid 36097702)
32. Nakayama, M., K. Ishidoh, N. Kayagaki, Y. Kojima, N. Yamaguchi, H. Nakano, E. Kominami, K. Okumura and H. Yagita: Multiple pathways of TWEAK-induced cell death. J Immunol 168, 734-743 (2002) (Pubitemid 34049574)
33. Nakayama, M., K. Ishidoh, Y. Kojima, N. Harada, E. Kominami, K. Okumura and H. Yagita: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170, 341-348 (2003) (Pubitemid 36026158)
34. Polek, T. C., M. Talpaz, B. G. Darnay and T. Spivak-Kroizman: TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR: evidence for a second TWEAK receptor. J Biol Chem 278, 32317-32323 (2003) (Pubitemid 37048427)
35. Felli, N., F. Pedini, A. Zeuner, E. Petrucci, U. Testa, C. Conticello, M. Biffoni, C. A. Di Cataldo, J. A. Winkles, C. Peschle and R. De Maria: Multiple members of the TNF superfamily contribute to IFN-γ-mediated inhibition of erythropoiesis. J Immunol 175, 1464-1472 (2005) (Pubitemid 41023046)
36. Perper, S. J., B. Browning, L. C. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, L. Runkel, M. Scott, G. J. Atkins, D. M. Findlay, T. S. Zheng and H. Hess: TWEAK is a novel arthritogenic mediator. J Immunol 177, 2610-2620 (2006) (Pubitemid 44201020)
37. Saas, P., J. Boucraut, P. R. Walker, A. Quiquerez, M. Billot, S. Desplat-Jego, Y. Chicheportiche and P. Dietrich: TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32, 102-107 (2000)
38. Chicheportiche, Y., R. Chicheportiche, I. Sizing, J. Thompson, C. B. Benjamin, C. Ambrose and J. Dayer: Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 4, 126-133 (2002) (Pubitemid 34257346)
39. Kawakita, T., K. Shiraki, Y. Yamanaka, Y. Yamaguchi, Y. Saitou, N. Enokimura, N. Yamamoto, H. Okano, K. Sugimoto, K. Murata and T. Nakano: Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 318, 726-733 (2004) (Pubitemid 38624215)
40. Ho, D. H., H. Vu, S. A. N. Brown, P. J. Donohue, H. N. Hanscom and J. A. Winkles: Soluble tumor necrosis factorlike weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 64, 8968-8972 (2004) (Pubitemid 39665505)
41. Polavarapu, R., M. C. Gongora, J. A. Winkles and M. Yepes: Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-κB pathway activation. J Neurosci 25, 10094-10100 (2005) (Pubitemid 41636205)
42. Maecker, H., E. Varfolomeev, F. Kischkel, D. Lawrence, H. LeBlanc, W. Lee, S. Hurst, D. Danilenko, J. Li, E. Filvaroff, B. Yang, D. Daniel and A. Ashkenazi: TWEAK attenuates the transition from innate to adaptive immunity. Cell 123, 931-944 (2005) (Pubitemid 41721037)
43. Zhang, X., J. A. Winkles, M. C. Gongora, R. Polavarapu, J. S. Michaelson, K. Hahm, L. Burkly, M. Friedman, X. J. Li and M. Yepes: TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab advance online publication 12 july (2006).
44. Zhao, H., A. Langerod, Y. Ji, K. W. Nowels, J. M. Nesland, R. Tibshirani, I. K. Bukholm, R. Karesen, D. Botstein, A. L. Borresen-Dale and S. S. Jeffrey: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15, 2523-2536 (2004) (Pubitemid 38691844)
45. Kawakita, T., K. Shiraki, Y. Yamanaka, Y. Yamaguchi, Y. Saitou, N. Enokimura, N. Yamamoto, H. Okano, K. Sugimoto, K. Murata and T. Nakano: Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol 26, 87-93 (2005)
46. Vakkila, J. and M. T. Lotze: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4, 641-648 (2004) (Pubitemid 39025049)
47. de Visser, K. E., A. Eichten and L. M. Coussens: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37 (2006) (Pubitemid 43053650)
48. Chicheportiche, Y., L. Fossati-Jimack, S. Moll, N. Ibnou-Zekri and S. Izui: Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 279, 162-165 (2000)
49. Nakayama, M., N. Kayagaki, N. Yamaguchi, K. Okumura and H. Yagita: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 192, 1373-1380 (2000)
50. Nakayama, M., N. Harada, K. Okumura and H. Yagita: Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306, 819-825 (2003) (Pubitemid 36776204)
51. Munoz-Garcia, B., J. L. Martin-Ventura, E. Martinez, S. Sanchez, G. Hernandez, L. Ortega, A. Ortiz, J. Egido and L. M. Blanco-Colio: Fn14 is upregulated in cytokinestimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37, 2044-2053 (2006) (Pubitemid 44309902)
52. Luo, J. L., H. Kamata and M. Karin: IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115, 2625-2632 (2005) (Pubitemid 41434385)
53. Kaduka, Y., K. Takeda, M. Nakayama, K. Kinoshita, H. Yagita and K. Okumura: TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochem Biophys Res Commun 331, 384-390 (2005) (Pubitemid 40602649)
54. Coussens, L. M. and Z. Werb: Inflammation and cancer. Nature 420, 860-867 (2002) (Pubitemid 36019639)
55. Lu, H., W. Ouyang and C. Huang: Inflammation, a key event in cancer development. Mol Cancer Res 4, 221-233 (2006)
56. Nathan, C: Points of control in inflammation. Nature 420, 846-852 (2002) (Pubitemid 36019637)
57. Krishnaswamy, G., J. Kelley, L. Yerra, J. K. Smith and D. S. Chi: Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 19, 91-104 (1999) (Pubitemid 29109625)
58. Muller, W. A: Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 82, 521-533 (2002) (Pubitemid 34522364)
59. Ulbrich, H., E. E. Eriksson and L. Lindbom: Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24, 640-647 (2003) (Pubitemid 37494786)
60. Balkwill, F., K. A. Charles and A. Mantovani: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (2005) (Pubitemid 40568680)
61. Albini, A., F. Tosetti, R. Benelli and D. M. Noonan: Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65, 10637-10641 (2005) (Pubitemid 41713327)
62. Lewis, C. E. and J. W. Pollard: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66, 605-612 (2006) (Pubitemid 43165918)
63. Bonizzi, G. and M. Karin: The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25, 280-288 (2004) (Pubitemid 38610351)
64. Karin, M. and F. R. Greten: NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5, 749-759 (2005) (Pubitemid 41400849)
65. Carmeliet, P: Angiogenesis in health and disease. Nat Med 9, 653-660 (2003) (Pubitemid 36749213)
66. Bergers, G. and L. E. Benjamin: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410 (2003) (Pubitemid 37328844)
67. Tonini, T., F. Rossi and P. P. Claudio: Molecular basis of angiogenesis and cancer. Oncogene 22, 6549-6556 (2003) (Pubitemid 37372334)
68. Cao, Y: Antiangiogenic cancer therapy. Semin Cancer Biol 14, 139-145 (2004) (Pubitemid 38234756)
69. Tew, W. P., D. P. Kelsen and D. H. Ilson: Targeted therapies for esophageal cancer. Oncologist 10, 590-601 (2005) (Pubitemid 41429122)
70. Layke, J. C. and P. P. Lopez: Esophageal cancer: a review and update. Am Fam Physician 73, 2187-2194 (2006) (Pubitemid 44031616)
71. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal and M. J. Thun: Cancer statistics, 2006. CA Cancer J Clin 56, 106-130 (2006)
72. Wang, S., M. Zhan, J. Yin, J. M. Abraham, Y. Mori, F. Sato, Y. Xu, A. Olaru, A. T. Berki, H. Li, K. Schulmann, T. Kan, J. P. Hamilton, B. Paun, M. M. Yu, Z. Jin, Y. Cheng, T. Ito, C. Mantzur, B. D. Greenwald and S. J. Meltzer: Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 25, 3346-3356 (2006) (Pubitemid 43846319)
73. Avila, M. A., C. Berasain, B. Sangro and J. Prieto: New therapies for hepatocellular carcinoma. Oncogene 25, 3866-3884 (2006) (Pubitemid 43980482)
74. Weigelt, B., J. L. Peterse and L. J. van't Veer: Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591-602 (2005) (Pubitemid 41081385)
75. Rich, J. N. and D. D. Bigner: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3, 430-446 (2004) (Pubitemid 38618125)
76. Louis, D. N: Molecular pathology of malignant gliomas. Ann Rev Pathol Mech Dis 1, 97-117 (2006)
77. Giese, A., R. Bjerkvig, M. E. Berens and M. Westphal: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636 (2003) (Pubitemid 46594118)
78. Salhia, B., N. L. Tran, M. Symons, J. A. Winkles, J. T. Rutka and M. E. Berens: Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn 6, 613-626 (2006) (Pubitemid 44179946)
79. Mariani, L., C. Beaudry, W. S. McDonough, D. B. Hoelzinger, T. Demuth, K. R. Ross, T. Berens, S. W. Coons, G. Watts, J. M. Trent, J. S. Wei, A. Giese and M. E. Berens: Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 53, 161-176 (2001) (Pubitemid 33034689)
80. Tran, N. L., W. S. McDonough, B. A. Savitch, S. P. Fortin, J. A. Winkles, M. Symons, M. Nakada, H. E. Cunliffe, G. Hostetter, D. B. Hoelzinger, J. L. Rennert, J. S. Michaelson, L. C. Burkly, C. A. Lipinski, J. C. Loftus, L. Mariani and M. E. Berens: Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and NF-κB and correlate with poor patient outcome. Cancer Res 66, 9535-9542 (2006) (Pubitemid 44623652)
81. Biswas, D. K., Q. Shi, S. Baily, I. Strickland, S. Ghosh, A. B. Pardee and J. D. Iglehart: NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101, 10137-10142 (2004) (Pubitemid 38891208)
82. Nagai, S., K. Washiyama, M. Kurimoto, A. Takaku, S. Endo and T. Kumanishi: Aberrant nuclear factor-κB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 96, 909-917 (2002) (Pubitemid 34415406)
83. Harris, A. L: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47 (2002) (Pubitemid 37328806)
84. Semenza, G. L: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732 (2003) (Pubitemid 37328811)
85. Yepes, M., S. A. N. Brown, E. G. Moore, E. P. Smith, D. A. Lawrence and J. A. Winkles: A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 166, 511-520 (2005) (Pubitemid 40189047)
86. Tanabe, K., I. Bonilla, J. A. Winkles and S. M. Strittmatter: Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 23, 9675-9686 (2003) (Pubitemid 37352067)
87. Desplat-Jego, S., R. Creidy, S. Varriale, N. Allaire, Y. Luo, D. Bernard, K. Hahm, L. Burkly and J. Boucraut: Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 117, 15-23 (2005) (Pubitemid 41725465)